Literature DB >> 6338344

Cryptococcemia.

J R Perfect, D T Durack, H A Gallis.   

Abstract

Previous reports have emphasized that cryptococcemia is almost uniformly fatal. To define the clinical course and prognostic and therapeutic implications of cryptococcemia, we studied 15 patients treated at this medical center over the past 7 years. Cryptococcemia was strongly associated with corticosteroid therapy, especially when the dosage had recently been increased. Meningitis was common (but not invariably present) in these patients, characteristically with a large burden of organisms in the cerebrospinal fluid. Cryptococcemia developed during hospitalization in one-third of our patients; this high rate of nosocomial infection emphasizes that C. neoformans infection should be considered in febrile, immunocompromised patients even when the initial work-up is negative. Most of these patients were treated with amphotericin B plus 5-fluorocytosine. Although the one-year survival rate of 4/15 (29%) was dismal, no patient died from uncontrolled cryptococcal infection. Other infections, which developed before, during or after cryptococcemia was diagnosed, were the major immediate cause of morbidity and mortality. The progress of underlying diseases and the outcome of concomitant infections in these patients were more important determinants of survival than was cryptococcemia itself.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6338344     DOI: 10.1097/00005792-198303000-00003

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  40 in total

1.  Antibody response to Cryptococcus neoformans proteins in rodents and humans.

Authors:  L C Chen; D L Goldman; T L Doering; L a Pirofski; A Casadevall
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

Review 2.  Cavitary pulmonary disease.

Authors:  L Beth Gadkowski; Jason E Stout
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

3.  Intraabdominal cryptococcal lymphadenitis in a patient with systemic lupus erythematosus.

Authors:  Sang-Hyon Kim; Sung-Dong Kim; Hae-Rim Kim; Chong-Hyeon Yoon; Sang-Heon Lee; Ho-Youn Kim; Sung-Hwan Park
Journal:  J Korean Med Sci       Date:  2005-12       Impact factor: 2.153

Review 4.  Infections in solid-organ transplant recipients.

Authors:  R Patel; C V Paya
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

5.  Dynamic and heterogeneous mutations to fluconazole resistance in Cryptococcus neoformans.

Authors:  J Xu; C Onyewu; H J Yoell; R Y Ali; R J Vilgalys; T G Mitchell
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

6.  Cryptococcosis in AIDS patients: observations concerning CNS involvement.

Authors:  T Weinke; G Rögler; C Sixt; B de Matos-Marques; H D Pohle; F Staib; M Seibold
Journal:  J Neurol       Date:  1989-01       Impact factor: 4.849

7.  Use of a suspension array for rapid identification of the varieties and genotypes of the Cryptococcus neoformans species complex.

Authors:  Mara R Diaz; Jack W Fell
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

8.  Therapy of Cryptococcal Meningitis in non-HIV-infected Patients.

Authors:  Peter G. Pappas
Journal:  Curr Infect Dis Rep       Date:  2001-08       Impact factor: 3.725

9.  Cutaneous cryptococcal infection presenting as vulvar lesion.

Authors:  K S Blocher; J A Weeks; R C Noble
Journal:  Genitourin Med       Date:  1987-10

10.  Disseminated cryptococcosis in HIV-uninfected patients.

Authors:  Y-M Chuang; Y-C Ho; H-T Chang; C-J Yu; P-C Yang; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-04       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.